Nukkleus Stock Current Liabilities
| NUKK Stock | USD 1.52 0.01 0.65% |
Nukkleus fundamentals help investors to digest information that contributes to Nukkleus' financial success or failures. It also enables traders to predict the movement of Nukkleus Stock. The fundamental analysis module provides a way to measure Nukkleus' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Nukkleus stock.
Total Current Liabilities is expected to rise to about 9 M this year. Non Current Liabilities Total is expected to rise to about 285.1 K this year. Nukkleus | Current Liabilities |
Nukkleus Company Current Liabilities Analysis
Nukkleus' Current Liabilities is the company's short term debt. This usually includes obligations that are due within the next 12 months or within one fiscal year. Current liabilities are very important in analyzing a company's financial health as it requires the company to convert some of its current assets into cash.
Current Nukkleus Current Liabilities | 2.56 M |
Most of Nukkleus' fundamental indicators, such as Current Liabilities, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Nukkleus is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Nukkleus Current Liabilities Driver Correlations
Understanding the fundamental principles of building solid financial models for Nukkleus is extremely important. It helps to project a fair market value of Nukkleus Stock properly, considering its historical fundamentals such as Current Liabilities. Since Nukkleus' main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Nukkleus' historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Nukkleus' interrelated accounts and indicators.
Click cells to compare fundamentals
Nukkleus Current Liabilities Historical Pattern
Today, most investors in Nukkleus Stock are looking for potential investment opportunities by analyzing not only static indicators but also various Nukkleus' growth ratios. Consistent increases or drops in fundamental ratios usually indicate a possible pattern that can be successfully translated into profits. However, when comparing two companies, knowing each company's current liabilities growth rates may not be enough to decide which company is a better investment. That's why investors frequently use a static breakdown of Nukkleus current liabilities as a starting point in their analysis.
Nukkleus Current Liabilities |
| Timeline |
Current liabilities appear on the company's balance sheet and include all short term debt accounts, accounts and notes payable, accrued liabilities as well as current payments due on the long-term loans. One of the most useful applications of Current Liabilities is the current ratio which is defined as current assets divided by its current liabilities. High current ratios mean that current assets are more than sufficient to pay off current liabilities.
| Competition |
Nukkleus Total Current Liabilities
Total Current Liabilities |
|
In accordance with the recently published financial statements, Nukkleus has a Current Liabilities of 2.56 M. This is 99.99% lower than that of the Software sector and significantly higher than that of the Information Technology industry. The current liabilities for all United States stocks is 99.97% higher than that of the company.
Nukkleus Current Liabilities Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Nukkleus' direct or indirect competition against its Current Liabilities to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Nukkleus could also be used in its relative valuation, which is a method of valuing Nukkleus by comparing valuation metrics of similar companies.Nukkleus is currently under evaluation in current liabilities category among its peers.
Nukkleus Current Valuation Drivers
We derive many important indicators used in calculating different scores of Nukkleus from analyzing Nukkleus' financial statements. These drivers represent accounts that assess Nukkleus' ability to generate profits relative to its revenue, operating costs, and shareholders' equity. Below are some of Nukkleus' important valuation drivers and their relationship over time.
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Market Cap | 352.3M | 353.2M | 590.2M | 669.0M | 602.1M | 632.2M | |
| Enterprise Value | 357.2M | 352.5M | 353.4M | 593.5M | 534.1M | 273.9M |
Nukkleus Fundamentals
| Return On Equity | -7.42 | ||||
| Return On Asset | -1.15 | ||||
| Profit Margin | (2.53) % | ||||
| Operating Margin | (7.94) % | ||||
| Current Valuation | 6.1 M | ||||
| Shares Outstanding | 2.67 M | ||||
| Shares Owned By Insiders | 27.49 % | ||||
| Shares Owned By Institutions | 1.58 % | ||||
| Number Of Shares Shorted | 21.68 K | ||||
| Price To Earning | (40.00) X | ||||
| Price To Book | 0.69 X | ||||
| Price To Sales | 0.38 X | ||||
| Revenue | 16.22 M | ||||
| Gross Profit | (661.4 K) | ||||
| EBITDA | (1.49 M) | ||||
| Net Income | (11.85 M) | ||||
| Cash And Equivalents | 23.14 K | ||||
| Total Debt | 3.65 M | ||||
| Current Ratio | 0.22 X | ||||
| Book Value Per Share | (6.61) X | ||||
| Cash Flow From Operations | 1.62 M | ||||
| Short Ratio | 0.03 X | ||||
| Earnings Per Share | (19.36) X | ||||
| Number Of Employees | 12 | ||||
| Beta | -0.32 | ||||
| Market Capitalization | 4.08 M | ||||
| Total Asset | 18.36 M | ||||
| Retained Earnings | (14.34 M) | ||||
| Working Capital | 895 K | ||||
| Current Asset | 3.46 M | ||||
| Current Liabilities | 2.56 M | ||||
| Net Asset | 18.36 M |
About Nukkleus Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Nukkleus's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Nukkleus using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Nukkleus based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Nukkleus Piotroski F Score and Nukkleus Altman Z Score analysis. For more information on how to buy Nukkleus Stock please use our How to buy in Nukkleus Stock guide.You can also try the Latest Portfolios module to quick portfolio dashboard that showcases your latest portfolios.
Is Application Software space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Nukkleus. If investors know Nukkleus will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Nukkleus listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (19.36) | Revenue Per Share 7.024 | Quarterly Revenue Growth (0.97) | Return On Assets (1.15) | Return On Equity (7.42) |
The market value of Nukkleus is measured differently than its book value, which is the value of Nukkleus that is recorded on the company's balance sheet. Investors also form their own opinion of Nukkleus' value that differs from its market value or its book value, called intrinsic value, which is Nukkleus' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Nukkleus' market value can be influenced by many factors that don't directly affect Nukkleus' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Nukkleus' value and its price as these two are different measures arrived at by different means. Investors typically determine if Nukkleus is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Nukkleus' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.